SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

14 Aug 2025 Evaluate
The Revenue for the quarter ended  June 2025 of Rs. 151.35 millions grew by 19.92 % from Rs. 126.21 millions.The Net Loss for the quarter ended June 2025 is Rs. -61.06 millions as compared to Net Loss of Rs. -13.64 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 further decreased to -66.61% as compared to -17.62% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 151.35 126.21 19.92 151.35 126.21 19.92 1092.99 396.42 175.72
Other Income 1.69 0.22 668.18 1.69 0.22 668.18 13.09 0.42 3016.67
PBIDT -66.61 -17.62 278.04 -66.61 -17.62 278.04 -86.84 -96.54 -10.05
Interest 6.28 4.07 54.30 6.28 4.07 54.30 36.14 26.61 35.81
PBDT -73.01 -21.69 236.61 -73.01 -21.69 236.61 -125.68 -122.78 2.36
Depreciation 8.47 6.49 30.51 8.47 6.49 30.51 17.82 15.94 11.79
PBT -81.48 -28.18 189.14 -81.48 -28.18 189.14 -143.50 -138.72 3.45
TAX -20.42 -14.54 40.44 -20.42 -14.54 40.44 -40.53 -103.92 -61.00
Deferred Tax -20.42 -14.54 40.44 -20.42 -14.54 40.44 -42.13 -103.92 -59.46
PAT -61.06 -13.64 347.65 -61.06 -13.64 347.65 -102.97 -34.80 195.89
Equity 369.84 354.84 4.23 369.84 354.84 4.23 369.84 334.84 10.45
PBIDTM(%) -44.01 -13.96 215.24 -44.01 -13.96 215.24 -7.95 -24.35 -67.37

Oxygenta Pharma Share Price

58.00 1.77 (3.15%)
21-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×